Design and Synthesis of a Biocompatible 1D Coordination Polymer as Anti-Breast Cancer Drug Carrier, 5-Fu: In Vitro and in Vivo Studies

Polymeric nanomaterials-based theranostic platforms for triple-negative breast cancer (TNBC) treatment

Breast cancer, the second leading global cause of death, affects 2.1 million women annually, with an alarming 15 percent mortality rate. Among its diverse forms, Triple-negative breast cancer (TNBC) emerges as the deadliest, characterized by the absence of hormone receptors. This article underscores the urgent need for innovative treatment approaches in tackling TNBC, emphasizing the transformative potential of polymeric nanomaterials (PNMs). Evolved through nanotechnology, PNMs offer versatile biomedical applications, particularly in addressing the intricate challenges of TNBC. The synthesis methods of PNMs, explored within the tumor microenvironment using cellular models, showcase their dynamic nature in cancer treatment. The article anticipates the future of TNBC therapeutics through the optimization of PNMs-based strategies, integrating them into photothermal (PT), photodynamic (PT), and hyperthermia therapy (HTT), drug delivery, and active tumor targeting strategies. Advancements in synthetic methods, coupled with a nuanced understanding of the tumor microenvironment, hold promise for personalized interventions. Comparative investigations of therapeutic models and a thorough exploration of polymeric nanoplatforms toxicological perspectives become imperative for ensuring efficacy and safety. We have explored the interdisciplinary collaboration between nanotechnology, oncology, and molecular biology as pivotal in translating PNMs innovations into tangible benefits for TNBC patients.

UoC-7: A Bimetallic K-Zn-MOF with an Anionic Framework Based on Fluorinated Trimesate Ligands Exhibiting a Large CO2 Uptake

In solvothermal reactions of Zn(NO3)2×6H2O with K(H2mF-BTC) or K(H2dF-BTC) in DMF/ethanol or DMA/ethanol solvent mixtures, single crystals of the MOFs UoC-7(1F) and UoC-7(2F) were obtained crystallizing in the hexagonal space group P63/m (no. 176) (H3BTC: 1,3,5-benzenetricarboxylic acid; mF-/dF: mono-/difluoro; DMF: N,N-dimethylformamide; DMA: N,N-dimethylacetamide; UoC: University of Cologne). According to the general composition [(CH3)2NH2][K2Zn3(mF-/dF-BTC)3(H2O)]×solvent, UoC-7 consists of an anionic bimetallic framework. The charge is compensated by a (CH3)2NH2 + cation stemming from the (partial) hydrolysis of the solvent. The crystal structure shows large channels along the hexagonal [001] direction, which accommodate the cations as well as solvent molecules. Surface areas (SBET) of 2740 m2/g (UoC-7(1F)) and 1643 m2/g (UoC-7(2F)) were obtained from N2 sorption measurements. UoC-7 shows structural similarities to the MOF NKU-521 with a 5-(1H-tetrazol-5-yl)isophthalate linker. Both MOFs exhibit a 4,7,8T14 topology. Despite smaller channels in UoC-7 compared to NKU-521, the CO2 uptake is considerably higher (~164 cm3/g at 1 bar/293 K) being one of the highest CO2 uptakes observed up to now.

A reliable QSPR model for predicting drug release rate from metal-organic frameworks: a simple and robust drug delivery approach

During the drug release process, the drug is transferred from the starting point in the drug delivery system to the surface, and then to the release medium. Metal-organic frameworks (MOFs) potentially have unique features to be utilized as promising carriers for drug delivery, due to their suitable pore size, high surface area, and structural flexibility. The loading and release of various therapeutic drugs through the MOFs are effectively accomplished due to their tunable inorganic clusters and organic ligands. Since the drug release rate percentage (RES%) is a significant concern, a quantitative structure-property relationship (QSPR) method was applied to achieve an accurate model predicting the drug release rate from MOFs. Structure-based descriptors, including the number of nitrogen and oxygen atoms, along with two other adjusted descriptors, were applied for obtaining the best multilinear regression (BMLR) model. Drug release rates from 67 MOFs were applied to provide a precise model. The coefficients of determination (R2) for the training and test sets obtained were both 0.9999. The root mean square error for prediction (RMSEP) of the RES% values for the training and test sets were 0.006 and 0.005, respectively. To examine the precision of the model, external validation was performed through a set of new observations, which demonstrated that the model works to a satisfactory degree.

Stimuli-responsive spin crossover nanoparticles for drug delivery and DNA-binding studies

Aminated silica hybrid, spin-crossover (SCO) nanoparticles (AmNPs) coupled with (S)-naproxen (NAP) were proposed for potential drug nanocarriers through drug release experiments at various pH values. DNA- and albumin-binding studies were also carried out using diverse techniques in order to investigate the interaction of the nanoparticles with calf-thymus DNA and serum albumins and to determine the corresponding binding constants.

Effect of long noncoding RNA CCAT2 on drug sensitivity to 5-fluorouracil of breast cancer cells through microRNA-145 meditated by p53

The current study was set out to investigate the mechanism by which silenced long noncoding RNA (lncRNA) colon cancer-associated transcript 2 (CCAT2) modulates the cell growth, migration, invasion, and drug sensitivity of breast cancer (BC) cells to 5-fluorouracil (5-Fu) with the involvement of miR-145 and p53. First, high CCAT2 expression was presented in BC cells and tissues. Subsequently, the links between CCAT2 expression and BC clinicopathological features were analyzed. Highly-expressed CCAT2 was linked to lymph node metastasis, positive progesterone receptor, estrogen receptor, and Ki-67 of BC cells. Then, the gain- and loss-of-function approaches were performed to measure the regulatory role of CCAT2 in the biological processes of BC cells. Silencing of CCAT2 suppressed in vitro cell growth, proliferation, invasion, migration abilities, and epithelial-mesenchymal transformation, increased cell apoptosis, and enhanced drug sensitivity of BC cells. Silencing of CCAT2 upregulated miR-145, which was poorly expressed in drug-resistant BC cells. p53 can bind to the miR-145 promoter region and increase miR-145 expression. Upregulation of miR-145 induced by silencing of CCAT2 can be invalidated by p53-siRNA. To conclude, p53-induced activation of miR-145 could be inhibited by CCAT2, while overexpression of CCAT2 could improve the drug resistance of BC cells to 5-Fu.

Design, preparation and pharmacodynamics of ICG-Fe(Ⅲ) based HCPT nanocrystals against cancer

The use of nanocrystal technology to manufacture drug delivery systems intended to enhance therapeutic efficacy has attracted the attention of the pharmaceutical industry. However, the clinical application of nanocrystal drugs for injection is restricted by Ostwald ripening and the large-scale use of stabilizers such as polysorbate and lecithin, which have potential toxicity risks including hemolysis and allergies. Here, we designed an amorphous nanocrystal drug complex (IHNC), which is stabilizer-free and composed of indocyanine green (ICG) framework loading with a chemotherapeutic agent of 10-hydroxycamptothecin (HCPT). Considering the possibility of industrial manufacturing, IHNC was simply prepared with the assistance of ferric ion (III) via supramolecular assembly strategy. The theoretical result of Materials Studio simulation indicated that the prepared ICG-Fe(III) framework showed a stable spherical structure with the appropriate cavity for encapsulating the two drugs of HCPT and ICG with equal mass ratio. The IHNC was stable at physiological pH, with excellent PTT/PDT efficacy, and in vivo probing characteristics. The nanoscale size and reductive stimuli-responsiveness can be conducive to drug accumulation into the tumor site and rapid unloading of cargo. Moreover, such combination therapy showed synergistic photo/chemotherapy effect against 4T1 breast cancer and its tumor inhibition rate even up to 79.4%. These findings demonstrated that the nanocrystal drug delivery strategy could avoid the use of stabilizers and provide a new strategy for drug delivery for combination therapy.

A facile approach to prepare silica hybrid, spin-crossover water-soluble nanoparticles as potential candidates for thermally responsive MRI agents

A reverse micelle method was used for the synthesis of water-soluble silica hybrid, spin-crossover (SCO) nanoparticles (NPs). MRI experiments provided temperature dependent T2 values, indicating their potential use as smart MRI agents, while lyophilization of NP dispersions in water yielded powders with a preserved but modified thermal hysteretic magnetic profile.

Utilizing Edible Agar as a Carrier for Dual Functional Doxorubicin-Fe3O4 Nanotherapy Drugs

The purpose of this study was to use agar as a multifunctional encapsulating material to allow drug and ferromagnetism to be jointly delivered in one nanoparticle. We successfully encapsulated both Fe3O4 and doxorubicin (DOX) with agar as the drug carrier to obtain DOX-Fe3O4@agar. The iron oxide nanoparticles encapsulated in the carrier maintained good saturation of magnetization (41.9 emu/g) and had superparamagnetism. The heating capacity test showed that the specific absorption rate (SAR) value was 18.9 ± 0.5 W/g, indicating that the ferromagnetic nanoparticles encapsulated in the gel still maintained good heating capacity. Moreover, the magnetocaloric temperature could reach 43 °C in a short period of five minutes. In addition, DOX-Fe3O4@agar reached a maximum release rate of 85% ± 3% in 56 min under a neutral pH 7.0 to simulate the intestinal environment. We found using fluorescent microscopy that DOX entered HT-29 human colon cancer cells and reduced cell viability by 66%. When hyperthermia was induced with an auxiliary external magnetic field, cancer cells could be further killed, with a viability of only 15.4%. These results show that agar is an efficient multiple-drug carrier, and allows controlled drug release. Thus, this synergic treatment has potential application value for biopharmaceutical carrier materials.

Water Soluble Iron-Based Coordination Trimers as Synergistic Adjuvants for Pancreatic Cancer

Pancreatic cancer is a usually fatal disease that needs innovative therapeutic approaches since the current treatments are poorly effective. In this study, based on cell lines, triazole-based coordination trimers made with soluble Fe(II) in an aqueous media were explored for the first time as adjuvant agents for the treatment of this condition. These coordination complexes were effective at relatively high concentrations and led to an increase in reactive oxygen species (ROS) in two pancreatic cancer cell lines, PANC-1 and BXPC-3, and this effect was accompanied by a significant reduction in cell viability in the presence of gemcitabine (GEM). Importantly, the tested compounds enhanced the effect of GEM, an approved drug for pancreatic cancer, through apoptosis induction and downregulation of the mTOR pathway. Although further evaluation in animal-based models of pancreatic cancer is needed, these results open novel avenues for exploring these iron-based materials in biomedicine in general and in pancreatic cancer treatment.

Recent development of amorphous metal coordination polymers for cancer therapy

Nanoscale metal coordination polymers (NCPs), built from metal ions and organic ligands, have attracted tremendous interest in biomedical applications. This is mainly due to their mesoporous structure, tunable size and morphology and versatile functionality. NCPs can be further divided into nanoscale metal-organic frameworks (NMOFs) and amorphous coordination polymer particles (ACPPs) depending on their structural crystallinity. NMOFs as nanocarriers have been extensively reviewed. However, the highlights of ACPPs as theranostic nanoplatforms are still limited. In this review, the recent progress of ACPPs as theranostic nanoplatforms is summarized based on what types of organic linkers used. The ACPPs are divided into three main parts: photosensitizers-based ACPPs, chemical drugs-based ACPPs, and biomolecules-based ACPPs. Finally, the prospects and challenges of the ACPPs for enhanced biomedical applications are also discussed. STATEMENT OF SIGNIFICANCE: Over the last decades, amorphous metal coordination polymers (ACPPs), constructed by metal ions and organic linkers, have attracted enormous interest in cancer treatment owing to their high drug loading capability, facile synthetic procedures, low long-term toxicity, and mild preparation conditions. In this review, we highlight the recent progress of ACPPs for biomedical application based on different types of organic building blocks including photosensitizers, chemical drugs, and biomolecules. Moreover, the prospects and challenges of ACPPs for clinical application are also discussed. We hope this review entitled "Recent development of amorphous metal coordination polymers for cancer therapy" would arise the researchers' interest in this field to accelerate their clinical application in cancer therapy.

Design of Targeted Nanostructured Coordination Polymers (NCPs) for Cancer Therapy

Conventional cancer chemotherapy presents notable drug side effects due to non-selective action of the chemotherapeutics to normal cells. Nanoparticles decorated with receptor-specific ligands on the surface have shown an important role in improving site-selective binding, retention, and drug delivery to the cancer cells. This review summarizes the recent reported achievements using nanostructured coordination polymers (NCPs) with active targeting properties for cancer treatment in vitro and in vivo. Despite the controversy surrounding the effectivity of active targeting nanoparticles, several studies suggest that active targeting nanoparticles notably increase the selectivity and the cytotoxic effect in tumoral cells over the conventional anticancer drugs and non-targeted nanoparticle platform, which enhances drug efficacy and safety. In most cases, the nanocarriers have been endowed with remarkable capabilities such as stimuli-responsive properties, targeting abilities, or the possibility to be monitored by imaging techniques. Unfortunately, the lack of preclinical studies impedes the evaluation of these unique and promising findings for the translation of NCPs into clinical trials.

Rational design and latest advances of codelivery systems for cancer therapy

Current treatments have limited effectiveness in treating tumors. The combination of multiple drugs or treatment strategies is widely studied to improve therapeutic effect and reduce adverse effects of cancer therapy. The codelivery system is the key to realize combined therapies. It is necessary to design and construct different codelivery systems in accordance with the variable structures and properties of cargoes and vectors. This review presented the typical design considerations about codelivery vectors for cancer therapy and described the current state of codelivery systems from two aspects: different types of vectors and collaborative treatment strategies. The commonly used loading methods of cargoes into the vectors, including physical and chemical processes, are discussed in detail. Finally, we outline the challenges and perspectives about the improvement of codelivery systems.

Structural analysis and catalytic activity of tetranuclear metal carboxylate clusters with a [KZn3(μ3-OH)(OOCCPh3)6] or [Zn4(μ4-O)(OOCCPh3)6] central motif

Tetranuclear triphenylacetato zinc–potassium or zinc clusters of formula [K_xZn_4−x(μ₃-OH)_x(μ₄-O)_1−x(Ph₃CCOO)₆] where x = 0, 1, with interesting structural, physicochemical or catalytic properties were obtained.

Recent advances in metallopolymer-based drug delivery systems

Metallopolymers (MPs) or metal-containing polymers have shown great potential as new drug delivery systems (DDSs) due to their unique properties, including universal architectures, composition, properties and surface chemistry. Over the past few decades, the exponential growth of many new classes of MPs that deal with these issues has been demonstrated. This review presents and assesses the recent advances and challenges associated with using MPs as DDSs. Among the most widely used MPs for these purposes, metal complexes based on synthetic and natural polymers, coordination polymers, metal-organic frameworks, and metallodendrimers are distinguished. Particular attention is paid to the stimulus- and multistimuli-responsive metallopolymer-based DDSs. Of considerable interest is the use of MPs for combination therapy and multimodal systems. Finally, the problems and future prospects of using metallopolymer-based DDSs are outlined. The bibliography includes articles published over the past five years.

A Biocompatible GdIII–Organic Framework Incorporating Polar Pores for pH-Sensitive Anti-Cancer Drug Delivery and Inhibiting Human Bone Tumour Cells

With the aim of developing new and effective drug delivery systems for cancer treatments, great effort has been devoted to the field of porous metal–organic framework (MOF) platforms because of their controlled drug release performance, high drug loading, and acceptable biocompatibility. In this contribution, we report a MOF [Gd2(H2O)3(SDBA)3](DMA)3] (1, DMA=N,N-dimethylacetamide) with open O donor sites functionalised 1D pores, which has been fabricated using a bent polycarboxylic acid organic linker 4,4′-sulfonyldibenzoic acid (H2SDBA) under solvothermal conditions. Single crystal X-ray diffraction (SCRD), thermogravimetric analysis (TGA), elemental analysis, X-ray powder diffraction (XPRD), and Brunauer–Emmett–Teller (BET) analysis were used to characterise the as-prepared complex 1. 5-Fluorouracil (5-Fu) loaded 1 was soaked in phosphate buffer saline (PBS) and the invitro drug release performance was monitored by HPLC analysis under different pH conditions. At the pH values of 7.4 and 6.5, different profiles of pH-responsive release were achieved, indicating that the drug release performance of 5-Fu loaded 1 is pH sensitive. Grand Canonical Monte Carlo (GCMC) simulation results demonstrate that the open O donor sites in the framework of 1 account for the slower drug release rate. The prepared carrier is found to be bio-compatible with MG63 cells (cancerous tissue) and oral epidermal cells (normal tissue), when tested by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The 5-Fu loaded carrier also shows a promising growth inhibition effect towards the human bone tumour cells MG63.